Korro Bio KRRO
NASDAQ KRRO
$14.41 -1.32 (-8.39%)
At close: Nov 11, 2026 · 4:00 PM EST

Korro Bio (KRRO) Gains from Sales and Divestitures (2024 - 2026)

Updated

Korro Bio's Gains from Sales and Divestitures was $18,000 in Q4 2025, compared with -$357,000 a year earlier.

Analysis

Korro Bio (KRRO) Gains from Sales and Divestitures (2024 - 2026) Analysis & Trends

For FY2025, Gains from Sales and Divestitures at Korro Bio came in at -$63,000.

  • In earlier years, Gains from Sales and Divestitures was -$357,000 in FY2024, -$65,000 in FY2023 and -$16,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Korro Bio 281.05 Mn -128.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -7,000.00
Dec 31, 2025 18,000.00
Dec 31, 2024 -357,000.00
API Access

Korro Bio Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=KRRO&period=max&api_key=YOUR_API_KEY